UPREAL-PsA: Upadacitinib Maintains Efficacy in Psoriatic Arthritis at 24 Weeks

24-week results from the UPREAL show higher efficacy of upadacitinib among males with PsA, bio-naïve patients, and those with elevated baseline C-reactive protein.

Related Keywords

Italy ,Italian ,Pixabay Miller ,Luchetti Gentiloni ,Michele Maria Luchetti Gentiloni ,Marche Polytechnic University ,Drug Administration ,Janus Kinase ,Biological Sciences ,Marche Polytechnic ,Minimal Disease Activity ,Very Low Disease Activity ,Disease Activity Index ,Psoriatic Arthritis ,Res Ther ,